SCHEMBL164184

SCHEMBL164184

CC(C#N)c1ccc(Br)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.41
KDM4E B2RXH2 2/20 0.40
PYCR1 P32322 1/20 0.40
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP2A6 P11509 1/20 0.38
CTSK P43235 2/20 0.38
CYP1A2 P05177 1/20 0.38
ESR1 P03372 2/20 0.36
ESR2 Q92731 2/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
GFER P55789 1/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
HTR2A P28223 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
NAAA Q02083 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4160843 1.00 ALOX5 (0.41) ALOX5KDM4EPYCR1ALDH1A1HPGD
SCHEMBL6565095 0.87 ESR1 (0.43) ALDH1A1CYP1A2ESR1ESR2GAA
SCHEMBL955060 0.80 TYR (0.41) KDM4EPYCR1ALDH1A1HPGDSMN1; SMN2
SCHEMBL958687 0.78 ALDH1A1 (0.44) ALOX5ALDH1A1SMN1; SMN2CYP2A6ESR1
SCHEMBL10952365 0.77 ESR1 (0.47) ALOX5KDM4EPYCR1ALDH1A1HPGD
SCHEMBL4145904 0.76 MEN1 (0.38) KDM4EALDH1A1HPGDSMN1; SMN2ESR1
SCHEMBL909757 0.76 ADRB2 (0.50) ALDH1A1HPGDSMN1; SMN2CYP2A6CYP1A2
SCHEMBL450037 0.76 ESR1 (0.61) ALDH1A1SMN1; SMN2CYP1A2ESR1ESR2
SCHEMBL12263781 0.76 ESR1 (0.36) ALDH1A1CYP1A2ESR1ESR2CYP11B1
SCHEMBL8088810 0.76 LMNA (0.46) ALDH1A1HPGDSMN1; SMN2ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694513-A1 PYRAZOLO PYRIMIDINE DERIVATIVES Novartis AG (CH) 2014-02-12 EP claimed
WO-2012131633-A1 PYRAZOLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2012-10-04 WO claimed
CN-1778792-A Production of alpha, alpha-dimethyl-4-brombenethane SHANGHAI CHEMICAL REAGENTS INS (CN) 2006-05-31 CN claimed
CN-1322841-A Biologically catalytic synthesis of optically active alpha-methyl-4-bromobenzyl acetic acid or its derivative SHANGHAI INST ORGANIC CHEM (CN) 2001-11-21 CN claimed
EP-4558495-A1 HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 Bristol-Myers Squibb Company (US) 2025-05-28 EP disclosed
US-20250026766-A1 Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors BEIGENE, LTD. (KY) 2025-01-23 US disclosed
EP-4463456-A1 THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS BeiGene, Ltd. (KY) 2024-11-20 EP disclosed
US-20240343733-A1 COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS C4 THERAPEUTICS, INC. 2024-10-17 US disclosed
US-20240287076-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE C4 THERAPEUTICS, INC. 2024-08-29 US disclosed
EP-4367113-A1 COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS Biogen MA Inc. (US) 2024-05-15 EP disclosed
WO-2024097228-A1 COMPOUNDS TARGETING CDK11 AND METHODS OF USING THE SAME MELIORA THERAPEUTICS, INC. (US) 2024-05-10 WO disclosed
CN-117940414-A Compounds for targeting IRAK4 protein degradation 渤健马萨诸塞州股份有限公司 2024-04-26 CN disclosed
CN-1291648-A Rhodococcus sp.D12 and its culture method and application SHANGHAI INST ORGANIC CHEM (CN) 2001-04-18 CN disclosed
CN-1251523-A Sulfonamide derivatives LILLY CO ELI (US) 2000-04-26 CN disclosed
WO-2000006537-A1 N-SUBSTITUTED SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2000-02-10 WO disclosed
WO-2000006176-A1 AMIDOPHOSPHATE DERIVATIVES ELI LILLY AND COMPANY (US) 2000-02-10 WO disclosed
WO-2000006156-A1 AMIDE, CARBAMATE, AND UREA DERIVATIVES ELI LILLY AND COMPANY (US) 2000-02-10 WO disclosed
EP-0976744-A1 Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity ELI LILLY AND COMPANY (US) 2000-02-02 EP disclosed
EP-0860428-A2 Sulphonamide derivatives ELI LILLY AND COMPANY (US) 1998-08-26 EP disclosed
WO-1998033496-A1 SULPHONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 1998-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287076-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, SYK, LYN ALOX5 4682/4885KDM4E 772/4885PYCR1 4194/4885
US-20240343733-A1 COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS IRAK4, IRAK2, IRAK1 ALOX5 4782/4885KDM4E 293/4885PYCR1 4065/4885
US-20250026766-A1 Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors POLQ, POLK, POLI ALOX5 4458/4885KDM4E 2678/4885PYCR1 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.